SURMOUNT-3: Tirzepatide with Intensive Lifestyle

Trial design and sequential approach

SURMOUNT-3 (Wadden et al., Nat Med 2023) used a two-phase sequential design unique among the SURMOUNT and STEP programs¹. Phase 1 (weeks 1-12): all 806 enrolled with BMI ≥30 or ≥27 with comorbidity received intensive lifestyle intervention. Phase 2 (weeks 13-84): the 579 participants who lost ≥5% during Phase 1 were randomized 1:1 to once-weekly tirzepatide titrated to maximum tolerated (10 or 15 mg) or placebo, both with continued lifestyle. Primary endpoint: % weight change from week 12 to week 84.

Phase 1: lifestyle alone

During the 12-week intensive lifestyle, mean weight loss was 6.9%. The 579 participants achieving ≥5% loss represented 71.8% of enrolled — a substantially higher proportion than typical in less intensive programs. Mean weight loss in this responder cohort at week 12: 7.6%.

Phase 2: tirzepatide vs placebo

From week 12 to week 84, tirzepatide lost an additional 21.1%, while placebo regained 3.3% — treatment difference -24.4 percentage points (95% CI -26.5 to -22.4; P<0.001)¹.

Cumulatively from original baseline to week 84, tirzepatide achieved mean total weight loss of ~26.6%. This is the largest weight loss reported in any published GLP-1 RA trial through 2026. The 24.4 percentage-point treatment difference also represents the largest randomized contrast in the obesity pharmacotherapy literature.

Why the larger effect size

Two factors likely contributed to the larger effect vs SURMOUNT-1 (22.5% at 15 mg). First, lifestyle pre-selection enriched for participants who could lose weight, biasing the cohort toward responders. Second, the intensive lifestyle co-intervention during Phase 2 was more rigorous than in SURMOUNT-1.

These considerations apply to practice: patients who can engage with structured behavioral support concurrently with pharmacotherapy may achieve substantially better outcomes than those receiving medication alone with minimal lifestyle reinforcement.

Adverse events

GI events dominated the adverse event profile. Nausea, diarrhea, constipation, vomiting most common, predominantly during dose escalation, mostly mild-moderate¹. Discontinuation due to adverse events ~6% in tirzepatide vs ~2% in placebo. Cholelithiasis occurred in 5.0% of tirzepatide vs 1.4% of placebo, consistent with SURMOUNT-1. No new safety signals.

Related editorial coverage

• SURMOUNT-1 trial
• STEP-3 — semaglutide + IBT
• Semaglutide vs tirzepatide

Frequently asked questions

Largest weight loss in any tirzepatide trial?

SURMOUNT-3, combining tirzepatide with intensive lifestyle in selected lifestyle responders: ~26.6% mean weight loss at 84 weeks — the largest in any published GLP-1 RA trial.

Should I do intensive lifestyle before starting tirzepatide?

Sequential or combined intensive behavioral therapy with pharmacotherapy produces the strongest weight loss in randomized trials. The sequence matters less than ensuring both components are active concurrently.

SURMOUNT-3 vs SURMOUNT-1?

SURMOUNT-1 used standard lifestyle and showed 22.5% at 15 mg over 72 weeks. SURMOUNT-3 added intensive lifestyle and pre-selected responders, producing 26.6% over 84 weeks.

Was the lifestyle phase necessary?

Lifestyle pre-selected responders and provided ongoing behavioral support. The design cannot fully separate these effects from marginal tirzepatide benefit, but the combined approach produced the largest effect.

26% weight loss realistic in typical practice?

Achieving 26% requires intensive multidisciplinary support exceeding typical clinical settings. Most patients in standard practice achieve closer to SURMOUNT-1's 20-22% on 15 mg. SURMOUNT-3 represents an upper bound with optimal infrastructure.